Interfering with the Dimerization of the ERBB Receptors by Transmembrane Domain-Derived Peptides Inhibits Tumorigenic Growth in Vitro and in Vivo

Biochemistry

Volumn 55, Issue 39, 2016, Pages 5520-5530

  Bublil, Erez M ^a   Cohen, Tomer ^a   Arnusch, Christopher J ^a   Peleg, Adi ^a   Pines, Gur ^a   Lavi, Sara ^a   Yarden, Yosef ^a   Shai, Yechiel ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; AMINO ACIDS; CELL CULTURE; CHEMICAL ACTIVATION; CHEMOTHERAPY; DIMERIZATION; DISEASES; DRUG PRODUCTS; PEPTIDES; TUMORS;

C-TERMINAL DOMAINS; HUMAN CANCER CELLS; LOW CONCENTRATIONS; PANCREATIC CANCERS; TRANS-MEMBRANE DOMAINS; TRANSMEMBRANE DOMAIN; TYROSINE PHOSPHORYLATION; TYROSINE-KINASE RECEPTORS;

PROTEINS;

AMINO ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; GLYCOPHORIN A; NEU DIFFERENTIATION FACTOR; VASCULOTROPIN; MEMBRANE PROTEIN; PEPTIDE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CONTROLLED STUDY; DIMERIZATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MOUSE; NONHUMAN; PANCREAS TUMOR; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; CHEMISTRY; METABOLISM; NEOPLASM; PATHOLOGY; PHOSPHORYLATION; SEQUENCE HOMOLOGY; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; DIMERIZATION; HUMANS; IN VITRO TECHNIQUES; MEMBRANE PROTEINS; NEOPLASMS; PEPTIDES; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 84989950832     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/acs.biochem.6b00450     Document Type: Article

References (63)

1. Hynes, N. E. and MacDonald, G. (2009) ErbB receptors and signaling pathways in cancer Curr. Opin. Cell Biol. 21, 177-184 10.1016/j.ceb.2008.12.010
2. Zhang, J., Yang, P. L., and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9, 28-39 10.1038/nrc2559
3. Ratushny, V., Astsaturov, I., Burtness, B. A., Golemis, E. A., and Silverman, J. S. (2009) Targeting EGFR resistance networks in head and neck cancer Cell. Signalling 21, 1255-1268 10.1016/j.cellsig.2009.02.021
4. Yarden, Y. and Pines, G. (2012) The ERBB network: at last, cancer therapy meets systems biology Nat. Rev. Cancer 12, 553-563 10.1038/nrc3309
5. Arteaga, C. L. and Engelman, J. A. (2014) ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics Cancer Cell 25, 282-303 10.1016/j.ccr.2014.02.025
6. Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., Janakiraman, V., Scholz, R. P., Bowman, K. K., Lorenzo, M., Li, H., Wu, J., Yuan, W., Peters, B. A., Kan, Z., Stinson, J., Mak, M., Modrusan, Z., Eigenbrot, C., Firestein, R., Stern, H. M., Rajalingam, K., Schaefer, G., Merchant, M. A., Sliwkowski, M. X., de Sauvage, F. J., and Seshagiri, S. (2013) Oncogenic ERBB3 mutations in human cancers Cancer Cell 23, 603-617 10.1016/j.ccr.2013.04.012
7. Citri, A. and Yarden, Y. (2006) EGF-ERBB signalling: towards the systems level Nat. Rev. Mol. Cell Biol. 7, 505-516 10.1038/nrm1962
8. Avraham, R. and Yarden, Y. (2011) Feedback regulation of EGFR signalling: decision making by early and delayed loops Nat. Rev. Mol. Cell Biol. 12, 104-117 10.1038/nrm3048
9. Mujoo, K., Choi, B. K., Huang, Z., Zhang, N., and An, Z. (2014) Regulation of ERBB3/HER3 signaling in cancer Oncotarget 5, 10222-10236 10.18632/oncotarget.2655
10. Yarden, Y. (2001) The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities Eur. J. Cancer 37 (Suppl. 4) S3-S8 10.1016/S0959-8049(01)00230-1
11. Garrett, T. P., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Zhu, H. J., Walker, F., Frenkel, M. J., Hoyne, P. A., Jorissen, R. N., Nice, E. C., Burgess, A. W., and Ward, C. W. (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha Cell 110, 763-773 10.1016/S0092-8674(02)00940-6
12. Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J. H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., and Yokoyama, S. (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains Cell 110, 775-787 10.1016/S0092-8674(02)00963-7
13. Zhang, X., Gureasko, J., Shen, K., Cole, P. A., and Kuriyan, J. (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor Cell 125, 1137-1149 10.1016/j.cell.2006.05.013
14. Red Brewer, M., Choi, S. H., Alvarado, D., Moravcevic, K., Pozzi, A., Lemmon, M. A., and Carpenter, G. (2009) The juxtamembrane region of the EGF receptor functions as an activation domain Mol. Cell 34, 641-651 10.1016/j.molcel.2009.04.034
15. Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., and Yarden, Y. (1999) The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors Proc. Natl. Acad. Sci. U. S. A. 96, 4995-5000 10.1073/pnas.96.9.4995
16. Jura, N., Endres, N. F., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., and Kuriyan, J. (2009) Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment Cell 137, 1293-1307 10.1016/j.cell.2009.04.025
17. Citri, A., Skaria, K. B., and Yarden, Y. (2003) The deaf and the dumb: the biology of ErbB-2 and ErbB-3 Exp. Cell Res. 284, 54-65 10.1016/S0014-4827(02)00101-5
18. Gala, K. and Chandarlapaty, S. (2014) Molecular pathways: HER3 targeted therapy Clin. Cancer Res. 20, 1410-1416 10.1158/1078-0432.CCR-13-1549
19. Spector, N. (2008) Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab Clin. Breast Cancer 8 (Suppl. 3) S94-S99 10.3816/CBC.2008.s.005
20. Adams, G. P. and Weiner, L. M. (2005) Monoclonal antibody therapy of cancer Nat. Biotechnol. 23, 1147-1157 10.1038/nbt1137
21. Baselga, J., Cortes, J., Kim, S. B., Im, S. A., Hegg, R., Im, Y. H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., Clark, E., Benyunes, M. C., Ross, G., and Swain, S. M. (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer N. Engl. J. Med. 366, 109-119 10.1056/NEJMoa1113216
22. Schoeberl, B., Faber, A. C., Li, D., Liang, M. C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L., Fulgham, A., Song, Y., Nielsen, U. B., Engelman, J. A., and Wong, K. K. (2010) An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation Cancer Res. 70, 2485-2494 10.1158/0008-5472.CAN-09-3145
23. Fitzgerald, J. B., Johnson, B. W., Baum, J., Adams, S., Iadevaia, S., Tang, J., Rimkunas, V., Xu, L., Kohli, N., Rennard, R., Razlog, M., Jiao, Y., Harms, B. D., Olivier, K. J., Jr., Schoeberl, B., Nielsen, U. B., and Lugovskoy, A. A. (2014) MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors Mol. Cancer Ther. 13, 410-425 10.1158/1535-7163.MCT-13-0255
24. Tanner, K. G. and Kyte, J. (1999) Dimerization of the extracellular domain of the receptor for epidermal growth factor containing the membrane-spanning segment in response to treatment with epidermal growth factor J. Biol. Chem. 274, 35985-35990 10.1074/jbc.274.50.35985
25. Fink, A., Reuven, E. M., Arnusch, C. J., Shmuel-Galia, L., Antonovsky, N., and Shai, Y. (2013) Assembly of the TLR2/6 transmembrane domains is essential for activation and is a target for prevention of sepsis J. Immunol. 190, 6410-6422 10.4049/jimmunol.1202033
26. Reuven, E. M., Ali, M., Rotem, E., Schwarzter, R., Gramatica, A., Futerman, A. H., and Shai, Y. (2014) The HIV-1 envelope transmembrane domain binds TLR2 through a distinct dimerization motif and inhibits TLR2-mediated responses PLoS Pathog. 10, e1004248 10.1371/journal.ppat.1004248
27. Gerber, D., Sal-Man, N., and Shai, Y. (2004) Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization J. Biol. Chem. 279, 21177-21182 10.1074/jbc.M400847200
28. Mendrola, J. M., Berger, M. B., King, M. C., and Lemmon, M. A. (2002) The single transmembrane domains of ErbB receptors self-associate in cell membranes J. Biol. Chem. 277, 4704-4712 10.1074/jbc.M108681200
29. Cymer, F. and Schneider, D. (2010) Transmembrane helix-helix interactions involved in ErbB receptor signaling Cell adhesion & migration 4, 299-312 10.4161/cam.4.2.11191
30. Weiner, D. B., Kokai, Y., Wada, T., Cohen, J. A., Williams, W. V., and Greene, M. I. (1989) Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein Oncogene 4, 1175-1183
31. Bargmann, C. I., Hung, M. C., and Weinberg, R. A. (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 Cell 45, 649-657 10.1016/0092-8674(86)90779-8
32. Brosig, B. and Langosch, D. (1998) The dimerization motif of the glycophorin A transmembrane segment in membranes: importance of glycine residues Protein Sci. 7, 1052-1056 10.1002/pro.5560070423
33. Lemmon, M. A., Flanagan, J. M., Hunt, J. F., Adair, B. D., Bormann, B. J., Dempsey, C. E., and Engelman, D. M. (1992) Glycophorin A dimerization is driven by specific interactions between transmembrane alpha-helices J. Biol. Chem. 267, 7683-7689
34. Fleishman, S. J., Schlessinger, J., and Ben-Tal, N. (2002) A putative molecular-activation switch in the transmembrane domain of erbB2 Proc. Natl. Acad. Sci. U. S. A. 99, 15937-15940 10.1073/pnas.252640799
35. Escher, C., Cymer, F., and Schneider, D. (2009) Two GxxxG-like motifs facilitate promiscuous interactions of the human ErbB transmembrane domains J. Mol. Biol. 389, 10-16 10.1016/j.jmb.2009.04.002
36. Langosch, D., Brosig, B., Kolmar, H., and Fritz, H. J. (1996) Dimerisation of the glycophorin A transmembrane segment in membranes probed with the ToxR transcription activator J. Mol. Biol. 263, 525-530 10.1006/jmbi.1996.0595
37. Gerber, D., Sal-Man, N., and Shai, Y. (2004) Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization J. Biol. Chem. 279, 21177-21182 10.1074/jbc.M400847200
38. Joce, C., Wiener, A., and Yin, H. (2011) Transmembrane domain oligomerization propensity determined by ToxR assay J. Visualized Exp. 10.3791/2721
39. Trafny, E. A., Lewandowski, R., Zawistowska-Marciniak, I., and Stepinska, M. (2013) Use of MTT assay for determination of the biofilm formation capacity of microorganisms in metalworking fluids World J. Microbiol. Biotechnol. 29, 1635-1643 10.1007/s11274-013-1326-0
40. Segev-Zarko, L., Saar-Dover, R., Brumfeld, V., Mangoni, M. L., and Shai, Y. (2015) Mechanisms of biofilm inhibition and degradation by antimicrobial peptides Biochem. J. 468, 259-270 10.1042/BJ20141251
41. Deupi, X., Olivella, M., Govaerts, C., Ballesteros, J. A., Campillo, M., and Pardo, L. (2004) Ser and Thr residues modulate the conformation of pro-kinked transmembrane alpha-helices Biophys. J. 86, 105-115 10.1016/S0006-3495(04)74088-6
42. Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., 3rd, and Hynes, N. E. (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation Proc. Natl. Acad. Sci. U. S. A. 100, 8933-8938 10.1073/pnas.1537685100
43. Sithanandam, G., Fornwald, L. W., Fields, J., and Anderson, L. M. (2005) Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549 Oncogene 24, 1847-1859 10.1038/sj.onc.1208381
44. Tanner, B., Hasenclever, D., Stern, K., Schormann, W., Bezler, M., Hermes, M., Brulport, M., Bauer, A., Schiffer, I. B., Gebhard, S., Schmidt, M., Steiner, E., Sehouli, J., Edelmann, J., Lauter, J., Lessig, R., Krishnamurthi, K., Ullrich, A., and Hengstler, J. G. (2006) ErbB-3 predicts survival in ovarian cancer J. Clin. Oncol. 24, 4317-4323 10.1200/JCO.2005.04.8397
45. Mills, G. B. and Yarden, Y. (2010) The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3 Cancer Cell 17, 217-218 10.1016/j.ccr.2010.02.023
46. Sheng, Q., Liu, X., Fleming, E., Yuan, K., Piao, H., Chen, J., Moustafa, Z., Thomas, R. K., Greulich, H., Schinzel, A., Zaghlul, S., Batt, D., Ettenberg, S., Meyerson, M., Schoeberl, B., Kung, A. L., Hahn, W. C., Drapkin, R., Livingston, D. M., and Liu, J. F. (2010) An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells Cancer Cell 17, 298-310 10.1016/j.ccr.2009.12.047
47. Gregory, C. W., Whang, Y. E., McCall, W., Fei, X., Liu, Y., Ponguta, L. A., French, F. S., Wilson, E. M., and Earp, H. S., 3rd (2005) Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth Clin. Cancer Res. 11, 1704-1712 10.1158/1078-0432.CCR-04-1158
48. Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C. M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., and Janne, P. A. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316, 1039-1043 10.1126/science.1141478
49. Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., and Moasser, M. M. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 Nature 445, 437-441 10.1038/nature05474
50. Wang, S., Huang, X., Lee, C. K., and Liu, B. (2010) Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin Oncogene 29, 4225-4236 10.1038/onc.2010.180
51. van der Horst, E. H., Murgia, M., Treder, M., and Ullrich, A. (2005) Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies Int. J. Cancer 115, 519-527 10.1002/ijc.20867
52. Manolios, N., Collier, S., Taylor, J., Pollard, J., Harrison, L. C., and Bender, V. (1997) T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease Nat. Med. 3, 84-88 10.1038/nm0197-84
53. Bennasroune, A., Fickova, M., Gardin, A., Dirrig-Grosch, S., Aunis, D., Cremel, G., and Hubert, P. (2004) Transmembrane peptides as inhibitors of ErbB receptor signaling Mol. Biol. Cell 15, 3464-3474 10.1091/mbc.E03-10-0753
54. He, L., Shobnam, N., and Hristova, K. (2011) Specific inhibition of a pathogenic receptor tyrosine kinase by its transmembrane domain Biochim. Biophys. Acta, Biomembr. 1808, 253-259 10.1016/j.bbamem.2010.08.007
55. Arpel, A., Sawma, P., Spenle, C., Fritz, J., Meyer, L., Garnier, N., Velazquez-Quesada, I., Hussenet, T., Aci-Seche, S., Baumlin, N., Genest, M., Brasse, D., Hubert, P., Cremel, G., Orend, G., Laquerriere, P., and Bagnard, D. (2014) Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis Cell Rep. 8, 1714-1721 10.1016/j.celrep.2014.07.044
56. Bocharov, E. V., Lesovoy, D. M., Pavlov, K. V., Pustovalova, Y. E., Bocharova, O. V., and Arseniev, A. S. (2016) Alternative packing of EGFR transmembrane domain suggests that protein-lipid interactions underlie signal conduction across membrane Biochim. Biophys. Acta, Biomembr. 1858, 1254-1261 10.1016/j.bbamem.2016.02.023
57. Herrera, A. I., Tomich, J. M., and Prakash, O. (2016) Membrane Interacting Peptides: a Review Curr. Protein Pept. Sci. 17, 1 10.2174/1389203717666160526123821
58. Strandberg, E. and Killian, J. A. (2003) Snorkeling of lysine side chains in transmembrane helices: how easy can it get? FEBS Lett. 544, 69-73 10.1016/S0014-5793(03)00475-7
59. Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., and Yarden, Y. (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor Mol. Cell. Biol. 16, 5276-5287 10.1128/MCB.16.10.5276
60. Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. (2005) Global cancer statistics, 2002 Ca-Cancer J. Clin. 55, 74-108 10.3322/canjclin.55.2.74
61. Rocha-Lima, C. M. (2008) New directions in the management of advanced pancreatic cancer: a review Anti-Cancer Drugs 19, 435-446 10.1097/CAD.0b013e3282fc9d11
62. Burris, H. A., 3rd, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J. Clin. Oncol. 15, 2403-2413
63. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., and Parulekar, W. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 25, 1960-1966 10.1200/JCO.2006.07.9525